Previously doing buisiness as Hanover Biotech in NH, DGI BioTechnologies, L.L.C. is a biotechnology-based research company formed to develop its proprietary small molecule drug lead discovery platform, called Diogenesis(TM). In today's modern pharmaceutical research family, DGI is considered a biotech assay tool and small molecule discovery company. DGI's proprietary process provides a universal in vitro assay platform for its small molecule drug lead discovery. The company is in the final stages of validating its new discovery process. Using in-house developed site-directed assays, DGI is now running automated high-throughput screens (HTS) utilizing large combinatorial small molecule chemical libraries provided by two of its partners. The company has developed its Diogenesis(TM) service by first creating large and diverse libraries of antibodies (GRABLIB(TM)) and peptides (RAPIDLIB(TM)), selecting specific entities which interact with and regulate a number of receptors for protein hormones, and then labeling them for use in HTS assays. In addition, DGI has obtained its first surrogate ligand 3D pharmacophore through NMR analysis of one of its anti-receptor peptides. DGI will remain focused on identifying and optimizing via both HTS BioScreens(TM) and computer-based structural CompuScreens(TM) promising small molecule drug leads which regulate protein:protein interactions. The company is currently seeking royalty based licensing agreements and research partnerships with several pharmaceutical and biotechnology companies. DGI presently has discovery programs in anti-cancer, immunoregulators, neuroprotectives, and growth enhancers. DGI is majority owned by New Brunswick Scientific Co. Inc. (NASDAQ:NBSC), a manufacturer of research equipment and scientific instrumentation.
